Novartis (NVS) and Incyte Corp. (INCY) announced Monday that RUXCOVID Phase III study of ruxolitinib for hospitalized patients with COVID-19 failed to meet primary endpoint.
Ruxolitinib is an oral inhibitor of the JAK 1 and JAK 2 tyrosine kinases.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com